Summary of Belite Bio Conference Call Company Overview - **Company**: Belite Bio (NasdaqCM:BLTE) - **Product**: Tinlarebant, an oral treatment for Stargardt disease Industry Context - **Disease**: Stargardt disease, an orphan disease affecting the retina, leading to blindness - **Prevalence**: Approximately 53,000 patients in the U.S., with a global prevalence of about 1 in 7,000, making it one of the top 10 most prevalent inherited diseases [4][8][5] Core Points and Arguments - **Mechanism of Action**: - Stargardt disease is caused by mutations in the ABCA4 gene, leading to toxic accumulation of all-trans retinal in photoreceptors [12][13] - Tinlarebant works by antagonizing the retinol binding protein (RBP4), reducing retinal delivery to the eye and thereby decreasing toxic accumulation [14][15] - **Clinical Trials**: - **Phase 1B/2 Trial**: Showed stabilization of vision over 2 years with a significant reduction in disease progression compared to natural history studies [21][22] - **Phase 3 DRAGON Trial**: Enrolled 104 patients, demonstrating a 36% reduction in the progression rate of definitely decreased autofluorescence (DDAF) lesions over 2 years, statistically significant with a P value of 0.0033 [27][28] - Secondary endpoint showed a 34% reduction in DAF lesions, also statistically significant [28] - **Safety Profile**: - Reported 6 serious adverse events, with none related to the drug. Common mild side effects included longer dark adaptation times and temporary visual discoloration [37][40] - **Regulatory Plans**: - Anticipated FDA submission in the first half of the year, with potential approval in the first quarter of the following year [43][44] - Plans for submissions to other global regulators, including EMA and PMDA in Japan, with a focus on a single trial for multiple regulatory approvals [45][46] Additional Important Information - **Market Opportunity**: Stargardt disease represents a significant unmet medical need, with no approved treatments currently available [8] - **Geographic Variability**: Prevalence of ABCA4 mutations varies globally, with the highest rates in populations of African descent [58][60] - **Future Studies**: Ongoing PHOENIX trial for geographic atrophy, with expectations to outperform existing therapies [66] - **Commercial Strategy**: Focus on genetic testing to confirm ABCA4 mutations, essential for patient eligibility for Tinlarebant [73] Conclusion Belite Bio is positioned to address a significant unmet need in the treatment of Stargardt disease with its innovative oral therapy, Tinlarebant, backed by promising clinical trial results and a clear regulatory pathway. The company is also preparing for commercialization and expanding its research into related conditions.

Financial Data and Key Metrics Changes - For Q4 2025, R&D expenses were $14.6 million, up from $7.3 million in Q4 2024, primarily due to expenses related to the DRAGON II trial and lower Australian R&D tax incentives [9][10] - SG&A expenses increased to $13.5 million from $4.2 million in Q4 2024, driven by higher share-based compensation and professional service fees [11][12] - The net loss for Q4 2025 was $25.3 million, compared to a net loss of $10.1 million in Q4 2024 [12] - For the full year, R&D expenses were $45.4 million, up from $29.9 million in 2024, while SG&A expenses rose to $38.9 million from $10.1 million [13][14] - The full year net loss was $77.6 million, compared to a net loss of $36.1 million in 2024 [15] Business Line Data and Key Metrics Changes - The DRAGON trial met its primary efficacy endpoint with a 36% reduction in the growth rate of atrophy lesions compared to placebo, positioning the company for regulatory engagement [5] - Enrollment in the phase III PHOENIX trial was completed with 430 subjects [7] Company Strategy and Development Direction - The company aims for a transformative year in 2026, with a planned NDA submission to the FDA in Q2 2026 and commercialization preparations for Stargardt disease [8] - Key leadership positions have been filled, and the company is building its organization in various functions including sales and marketing [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming NDA submission and the potential for Tinlarebant to be the first approved therapy for Stargardt disease [4][8] - The company is focused on ensuring awareness among physicians and patients regarding the new treatment [33] Other Important Information - The company closed the year with $772.6 million in cash equivalents, significantly up from $145.2 million at the end of 2024, indicating a strong balance sheet [16] Q&A Session Summary Question: NDA submission and cash usage - The NDA will be a rolling submission, with DRAGON II data relevant for Japan only. The company expects R&D activities to cost about $150 million over the next three years, with commercialization costs between $150 million and $200 million [20][21] Question: Pricing guidance - While it's early to set a price, the average price for rare disease drugs in the US is around $350,000, and the company expects to perform better than that [25] Question: Launch timing and challenges - The expected launch is by Q1 2027, with a focus on genetic testing and patient awareness as key factors for success [32][33] Question: Ex-US regulatory strategy - The company prioritizes the FDA for NDA submission, with plans to follow up with EMA and other regions afterward [40][70] Question: Prevalence of Stargardt disease - The estimated prevalence of Stargardt disease in the US is about 53,000 patients, based on genetic databases [76][77]

Core Insights - Belite Bio announced successful topline results from the Phase 3 "DRAGON" trial of Tinlarebant, the first pivotal trial for treating Stargardt disease type 1 (STGD1), which currently has no approved treatments globally [1][3] Trial Results - The DRAGON trial enrolled 104 patients and met its primary efficacy endpoint, showing a statistically significant 36% reduction in the growth rate of retinal lesions compared to placebo, with a p-value of 0.0033 [2][6] - A post-hoc analysis indicated a consistent treatment effect with a p-value of <0.0001, reinforcing the efficacy of Tinlarebant [2][6] - The treatment also demonstrated a significant reduction in lesion growth in the fellow eye, with a 33.6% reduction (p = 0.041) [13] Safety Profile - Tinlarebant was well tolerated throughout the trial, with only four treatment-related discontinuations reported [6][20] - The safety profile was consistent with previous trials, with mild ocular adverse events such as xanthopsia and delayed dark adaptation [20] Regulatory Plans - Belite Bio plans to file a New Drug Application (NDA) with the US FDA in the first half of 2026 [6][9] - The drug has received multiple designations including Breakthrough Therapy and Orphan Drug Designation in the U.S., Europe, and Japan [9][17] Company Overview - Belite Bio is focused on developing novel therapeutics for degenerative retinal diseases, with Tinlarebant as its lead candidate [18] - The company is also evaluating Tinlarebant in ongoing trials for other retinal conditions, indicating a commitment to addressing significant unmet medical needs [18]

Core Insights - Belite Bio, Inc. has received acceptance from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for a Conditional Marketing Authorization application for Tinlarebant, aimed at treating Stargardt disease based on interim analysis results from the Phase 3 DRAGON trial [1][3][8] Company Overview - Belite Bio is a clinical-stage drug development company focused on novel therapeutics for degenerative retinal diseases with significant unmet medical needs, including Stargardt disease and geographic atrophy in advanced dry age-related macular degeneration [6] - The lead candidate, Tinlarebant, is an oral therapy designed to reduce the accumulation of vitamin A-based toxins in the eye, which are implicated in retinal diseases [5][6] Clinical Trial Details - The Phase 3 DRAGON trial is a randomized, double-masked, placebo-controlled study evaluating the safety and efficacy of Tinlarebant in 104 adolescent patients with Stargardt disease across 11 jurisdictions [4] - The primary efficacy endpoint of the trial is the growth rate of atrophic lesions, alongside safety and tolerability assessments [4] Regulatory Progress - The interim analysis results from the DRAGON trial met the criteria for the Conditional Marketing Authorization application, with final topline data expected to be reported in Q4 2025 [3][8] - The company is optimistic about the global submissions and potential approvals based on consistent feedback from major regulatory agencies [2]